Back to Report Store Home

Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • Published: Feb-2016
  • Report Code: GBIHC402MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Marketed Product Overview 18

Figure 2: Treatment Algorithm for Cancer Diagnosed at Stages I to III 22

Figure 3: Treatment Algorithm for Cancer Diagnosed at Stage IV 23

Figure 4: Developmental Pipeline Overview 26

Figure 5: Developmental Pipeline Molecular Target Categories 28

Figure 6: Molecular Target Category Comparison, Pipeline and Marketed Products 29

Figure 7: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets 31

Figure 8: First-in-Class Products in the Breast Cancer Pipeline, Part 1 32

Figure 9: First-in-Class Products in the Breast Cancer Pipeline, Part 2 33

Figure 10: First-in-Class Products in the Breast Cancer Pipeline, Part 3 34

Figure 11: First-in-Class Products in the Breast Cancer Pipeline, Part 4 35

Figure 12: First-in-Class Molecular Target Analysis Matrix 38

Figure 13: First-in-Class Molecular Target Analysis Matrix 39

Figure 14: First-in-Class Molecular Target Analysis Matrix 40

Figure 15: Pipeline Programs Targeting FGFR3 42

Figure 17: Pipeline Programs Targeting HER3 43

Figure 18: Pipeline Programs Targeting PDK1 44

Figure 19: Pipeline Programs Targeting Akt1 47

Figure 20: Pipeline Programs Targeting Akt2 48

Figure 21: Pipeline Programs Targeting Akt3 48

Figure 22: Pipeline Programs Targeting PI3K 49

Figure 23: Industry-Wide Deals by Stage of Development, 2006–2014 51

Figure 24: Industry Licensing Deal Values by Stage of Development ($m), 2006–2014 52

Figure 25: Global, Licensing Deals by Region and Value, 2006–2014 54

Figure 26: Global, Licensing Deals by Stage and Value, 2006–2014 55

Figure 27: Licensing Deals by Molecule Type, 2006–2014 56

Figure 28: Licensing Deals by Molecular Target, 2006–2014 56

Figure 29: Licensing Deals, 2006–2014 57

Figure 30: Licensing Deals, 2006–2014 58

Figure 31: Co-Development Deals, 2006–2014 59

Figure 32: Co-Development Deals, 2006–2014 60

Figure 33: Co-Development Deals by Molecule Type, 2006–2014 61

Figure 34: Co-Development Deals by Molecular Target, 2006–2014 61

Figure 35: Co-Development Deals, 2006–2014 62

Figure 36: First-in-Class Programs with no Prior Deal Involvement, Part 1 64

Figure 37: First-in-Class Programs with no Prior Deal Involvement, Part 2 65

Figure 38: First-in-Class Programs with no Prior Deal Involvement, Part 3 66

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards